News Detail
Chicago, 5 June 2023: Adjuvant osimertinib can improve overall survival (OS) in patients with EGFR-mutated, early-stage non-small-cell lung cancer (NSCLC), according to results from the ADAURA trial presented at the ASCO Annual Meeting 2023.1
Source : Cancer Therapy Advisor
lung cancer
Researchers
death
risk
study
Science News
ASCO 2023
non-small cell lung cancer
Related News
- Zydus gets warning as FDA highlights glass contamination concerns and others (12-09-2024)
- MPIDC allotted land to 36 industries in Medical Devices Park, investment of 1.8k crore (12-09-2024)
- DCC asks states and UTs to ensure implementation of revised Schedule M (12-09-2024)
- NPPA fixes retail price of 62 new drugs, extends CP of knee implants (12-09-2024)
- US FDA Issues Revised Guidance On Controlling Nitrosamine Impurities In Pharmaceuticals (12-09-2024)
- Bharat Biotech collaborates with US-based Alopexx to develop antimicrobial vaccine (12-09-2024)
- DCGI suspends permission to Entod pharma's 'Presvu Eye Drops', company to challenge order in court (11-09-2024)
- Diagnostic kits for early detection of Alzheimer’s and cancer launched (11-09-2024)
- FDI equity inflow into pharma sector grows to $236 million in Q1FY25 (11-09-2024)
- Steroid Use Could Raise Diabetes Risk (11-09-2024)